PIM kinases alter mitochondrial dynamics and chemosensitivity in lung cancer

Area of Science:

• Oncology
• Cell Biology
• Biochemistry

Background:

• Chemotherapy resistance is a significant challenge in treating non-small-cell lung cancer (NSCLC).
• The role of PIM kinases in regulating mitochondrial function and their impact on NSCLC treatment response remains unclear.

Purpose of the Study:

• To investigate the impact of PIM kinases on mitochondrial dynamics, reactive oxygen species (ROS) production, and chemotherapy response in NSCLC.
• To elucidate the signaling pathways involved in PIM kinase-mediated regulation of mitochondria in lung cancer.

Main Methods:

• Live-cell imaging and microscopy were employed to assess mitochondrial phenotype and ROS levels following PIM kinase inhibition or loss.
• Western blotting and immunohistochemistry were used to analyze protein expression and localization, including PIM1 and Drp1.
• In vitro and in vivo models of NSCLC were utilized to evaluate the synergistic effects of PIM inhibition and chemotherapy.

Main Results:

• Inhibition of PIM kinases led to excessive mitochondrial fission and increased mitochondrial superoxide production, elevating intracellular ROS.
• A mechanistic link was established between PIM1 and Drp1, demonstrating that PIM inhibition increases Drp1 levels and mitochondrial localization, causing significant mitochondrial fragmentation.
• An inverse correlation between PIM1 and Drp1 was observed in NSCLC patient samples.
• PIM inhibition sensitized NSCLC cells to chemotherapy, resulting in synergistic antitumor responses in vitro and in vivo.

Conclusions:

• PIM kinases play a crucial role in regulating mitochondrial dynamics and ROS production in NSCLC.
• The PIM1-Drp1 signaling axis is a key mediator of mitochondrial fission in lung cancer.
• Combining PIM kinase inhibitors with chemotherapy presents a promising therapeutic strategy for NSCLC due to synergistic antitumor activity.